Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.
Profitability
This table compares Xenetic Biosciences and Gilead Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenetic Biosciences | -75.90% | -40.62% | -34.97% |
| Gilead Sciences | -10.64% | -2.11% | -0.75% |
Volatility and Risk
Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Xenetic Biosciences and Gilead Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| Gilead Sciences | 0 | 6 | 23 | 0 | 2.79 |
Gilead Sciences has a consensus target price of $162.00, suggesting a potential downside of 5.66%. Given Gilead Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Xenetic Biosciences.
Insider and Institutional Ownership
15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Xenetic Biosciences and Gilead Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenetic Biosciences | $3.26 million | 1.47 | -$2.68 million | ($1.16) | -1.80 |
| Gilead Sciences | $29.44 billion | 7.23 | $8.51 billion | ($2.67) | -64.31 |
Gilead Sciences has higher revenue and earnings than Xenetic Biosciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Gilead Sciences beats Xenetic Biosciences on 10 of the 14 factors compared between the two stocks.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
